Ticker

Protara Therapeutics, Inc. (NASDAQ: TARA - Get Free Report) was the recipient of a large increase in short interest in the month of February. As of February 27th, there was short interest totaling 4,895,488 shares, an increase of 48.0% from the February 12th total of 3,308,046 shares. Based on an average daily volume of 1,590,962 shares,

Reported interim data from ADVANCED-2 trial in non-muscle invasive bladder cancer (NMIBC); TARA-002 demonstrated 68% complete response rate at six months in BCG-Unresponsive patients  Company expects to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 2H 2026 On track to initiate the ADVANCED-3 registrational trial in BCG-Naïve patients in 2H 2026 Received Breakthrough…

Protara Therapeutics (NASDAQ: TARA) executives outlined progress across the company's two clinical-stage programs during a fireside chat at Oppenheimer's 36th Annual Healthcare Life Sciences Conference, highlighting updated interim results from its ongoing non-muscle invasive bladder cancer (NMIBC) study of TARA-002 and providing an update on regulatory planning in lymphatic malformations (LMs). The company also…

Protara Therapeutics, Inc. (TARA) Discusses Interim Phase II Results for TARA-002 in Non-Muscle Invasive Bladder Cancer Transcript

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative…